Ursodeoxycholic Acid 300 mg Tablets
A trusted hepatoprotective agent for dissolving gallstones, managing Primary Biliary Cholangitis (PBC), and supporting liver health in cystic fibrosis patients. GMP certified formulation by Novique Life Sciences.
Brand Name: Eudica-300
Generic Name: Ursodeoxycholic Acid Tablets IP
Strength: 300 mg per tablet
Dosage Form: Film-coated tablets
Pack Size: 10 x 10 tablets
Primary Therapeutic Uses
Gallstone Dissolution
Reduces cholesterol concentration in bile to gradually dissolve non-calcified, cholesterol-rich gallstones. Provides a non-surgical treatment option for suitable patients, potentially avoiding the need for cholecystectomy.
Primary Biliary Cholangitis (PBC)
First-line therapy for this autoimmune liver disease. Improves liver enzyme levels, enhances bile flow, and helps slow disease progression. Provides symptomatic relief and may delay the need for liver transplantation.
Cystic Fibrosis Liver Support
Indicated for children aged 6 years and older with cystic fibrosis-associated liver disease. Helps manage biliary complications and supports overall liver function in these patients.
How Ursodeoxycholic Acid 300 mg Tablets Eudica-300 Works
Ursodeoxycholic Acid (UDCA) exerts its therapeutic effects through multiple complementary mechanisms:
Reduces Cholesterol
Decreases hepatic secretion of cholesterol into bile, reducing cholesterol saturation and promoting dissolution of cholesterol gallstones.
Replaces Toxic Bile Acids
Displaces endogenous, hydrophobic, potentially toxic bile acids with non-toxic UDCA in the enterohepatic circulation.
Protects Liver Cells
Exerts direct cytoprotective effects on hepatocytes and cholangiocytes, reducing inflammation and cellular damage.
Enhances Bile Flow
Stimulates hepatobiliary secretion and increases bile flow, which helps flush out toxins and metabolic byproducts.
Why Choose Eudica-300?
Proven Efficacy
Clinical studies demonstrate gallstone size reduction in 40-60% of patients when treated for 6-24 months with ursodeoxycholic acid tablets.
Excellent Tolerability
Mild side effects like diarrhea or nausea occur in less than 10% of patients. Well-established long-term safety profile with minimal adverse effects.
Novique Quality Assurance
Manufactured in GMP/ISO certified facilities ensuring consistent potency, purity, and pharmaceutical excellence in every batch.
Frequently Asked Questions
Eudica-300 is prescribed for dissolving cholesterol gallstones, treating Primary Biliary Cholangitis (PBC), and managing liver complications in cystic fibrosis patients aged 6+.
It decreases cholesterol production in the liver and bile, replaces toxic bile acids with non-toxic UDCA, and protects liver cells from damage through multiple cytoprotective mechanisms.
The standard dose is 8-10 mg/kg/day divided into 2-3 doses. For example, a 30kg adult would typically take one 300 mg tablet daily. Always follow physician instructions.
Most patients tolerate it well. Mild side effects like diarrhea or nausea may occur in less than 10% of patients. Rare side effects include itching or liver enzyme changes, which is why regular monitoring is recommended.
Clinical studies show 40-60% of patients experience gallstone size reduction when treated for 6-24 months with ursodeoxycholic acid tablets. Success depends on stone composition and patient adherence to therapy.
PCD Franchise Opportunity
Join over 1,000 successful partners across India with the Novique Life Sciences PCD Franchise program. We offer exclusive monopoly rights for marketing and distribution of Eudica-300 and our complete product portfolio in your territory.
As a franchise partner, you'll receive comprehensive marketing support, promotional materials, competitive pricing, and dedicated regional management assistance to build a profitable pharmaceutical business.
Request Franchise Details